Ascendiant Capital Markets Has Lowered Expectations for AIM ImmunoTech (NYSE:AIM) Stock Price

AIM ImmunoTech (NYSE:AIM) had its price objective cut by analysts at Ascendiant Capital Markets from $5.00 to $4.50 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, Maxim Group cut their price target on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, October 22nd.

AIM ImmunoTech Stock Performance

Shares of AIM stock opened at $0.22 on Tuesday. The company has a market capitalization of $13.99 million, a P/E ratio of -0.47 and a beta of -0.36. AIM ImmunoTech has a fifty-two week low of $0.16 and a fifty-two week high of $0.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a 50 day moving average price of $0.24 and a two-hundred day moving average price of $0.31.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC acquired a new position in AIM ImmunoTech Inc. (NYSE:AIM) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech at the end of the most recent quarter. 12.02% of the stock is currently owned by institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).